Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study

Published:2021-07 Issue: Volume:152 Page:215-222
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Soleimani Maryam^ORCID,Zou Kevin,Sunderland Katherine^ORCID,Struss Werner^ORCID,Eigl Bernie J.,Nappi Lucia^ORCID,Kollmannsberger Christian K.,Finch Daygen^ORCID,Noonan Krista^ORCID,Vergidis Joanna,Zulfiqar Muhammad,Chi Kim N.^ORCID,Khalaf Daniel J.

Funder

Bayer

Janssen Pharmaceuticals

Novartis

Daiichi-Sankyo

Roche

Sanofi

AstraZeneca

Bristol-Myers Squibb Canada

Pfizer

Astellas Pharma US

Prostate Cancer Foundation

AbbVie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Cancer statistics, 2020;Siegel;CA Canc J Clin,2020

2. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients;Boyle;Eur J Canc,2019

3. Management of castrate-resistant prostate cancer in older men;Ged;J Geriatr Oncol,2016

4. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL;Graff;Ann Oncol,2016

5. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial;Sternberg;Ann Oncol Off J Eur Soc Med Oncol,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes in studies regarding older patients with prostate cancer: A systematic review;Journal of Geriatric Oncology;2024-06

2. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27

3. A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer;European Urology Oncology;2024-03

4. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

5. Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis;Cancer Medicine;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3